ReviewPharmacology, biochemistry, and behavior2011
Cognitive enhancers in the treatment of substance use disorders: clinical evidence.
Review in Pharmacology, biochemistry, and behavior, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Effects of Exercise on Neural Changes in Inhibitory Control: An ALE Meta-Analysis of fMRI Studies.Frontiers in human neuroscience · 2022Pooled it
- Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions.Journal of psychiatry & neuroscience : JPN · 2014Pooled it
- Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders.Journal of addictive diseases · 2013Trial
- Acute effects of modafinil on brain resting state networks in young healthy subjects.PloS one · 2013Trial
- Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world.Contemporary clinical trials · 2012Trial
- Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use Disorders.Journal of addiction medicineTrial
- Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.The Journal of clinical psychiatryTrial
- Psychotropic medication non-adherence and its determinants among adult psychiatric patients in Ethiopia.Social psychiatry and psychiatric epidemiology · 2026Article
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Human laboratory models of reward in substance use disorder.Pharmacology, biochemistry, and behavior · 2024Review
- Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024Article
- Article
- Evaluation of two differentFrontiers in pharmacology · 2022Article
- Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, In Vitro Studies and Association withBiomolecules · 2020Article
- The cognitive cost of reducing relapse to cocaine-seeking with mGlu5 allosteric modulators.Psychopharmacology · 2020Article
- Cognition and addiction .Dialogues in clinical neuroscience · 2019Review
- Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.Frontiers in psychiatry · 2019Review
- Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2018Review
- Repetitive Transcranial Magnetic Stimulation for Wernicke-Korsakoff Syndrome: A Case Report.Annals of rehabilitation medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Attenuation of drug reward has been the major focus of medication development in the addiction area to date. With the growth of research in the area of cognitive neuroscience, the importance of executive function and inhibitory cognitive control in addictive disorders is becoming increasingly apparent. An emerging strategy in the pharmacotherapy of addictions and other psychiatric disorders involves the use of medications that improve cognitive function. In particular, agents that facilitate inhibitory and attentional control, improve abstraction, planning and mental flexibility could be beneficial in the treatment of substance use disorders. Because there are multiple neurotransmitter systems involved in the regulation of cognitive function, agents from a number of drug classes have been tested. In particular, agents acting through the cholinergic, adrenergic and glutamatergic systems have shown potential for improving cognitive function in a number of psychiatric and neurologic disorders, but most of these agents have not been tested in the treatment of individuals with substance use disorders. This manuscript provides a review of clinical data supporting the use of the major classes of cognitive enhancing agents in substance use disorders. Agents that have shown promise in cognitive enhancement in other disorders, and have a theoretical or mechanistic rationale for application to substance use disorders are also highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.